A Case of de novo Annular-plaque Type Psoriasis Following Oxford- AstraZeneca COVID-19 Vaccination

Curr Drug Saf. 2023 Apr 27;18(4):584-588. doi: 10.2174/1574886317666220613163327.

Abstract

Background: There have been increasing reported cases of new-onset or aggravation of pre-existing dermatoses after the implementation of COVID-19 vaccination.

Case presentation: An elderly male was presented with multiple annular scaly plaques all over the body two weeks following administration of the first dose of Oxford-AstraZeneca COVID-19 vaccine. The lesions further aggravated after taking the second dose of the vaccine. The clinical and histopathology features were suggestive of annular plaque psoriasis.

Conclusion: We report this first case of de novo plaque psoriasis following the Oxford- AstraZeneca COVID-19 vaccine, and it signifies a potential side effect of autoimmune reactivation after COVID vaccination.

Keywords: COVID-19 vaccine; Psoriasis; annular; astrazeneca; hypertension; psoriasis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • ChAdOx1 nCoV-19
  • Humans
  • Male
  • Psoriasis* / diagnosis
  • Vaccination

Substances

  • COVID-19 Vaccines
  • ChAdOx1 nCoV-19